Trends in Cancer Incidence in US Adolescents and Young Adults, 1973-2015.
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
28
1
2021
Statut:
epublish
Résumé
Previous studies have demonstrated that adolescents and young adults (AYAs) with cancer are a distinct cancer population; however, research on long-term epidemiological trends and characteristics of cancers in AYAs is lacking. To characterize the epidemiology of cancer in AYAs aged 15 to 39 years with respect to (1) patient demographic characteristics, (2) frequencies of cancer types, and (3) cancer incidence trends over time. This retrospective, serial cross-sectional, population-based study used registry data from the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 1973, to December 31, 2015 (SEER 9 and SEER 18). The study population was from geographically distinct US regions, chosen to represent the racial and ethnic heterogeneity of the country. Initial analyses were performed from January 1 to August 31, 2019. Incidence rates and descriptive epidemiological statistics for patients aged 15 to 39 years with invasive cancer. A total of 497 452 AYAs diagnosed from 1973 to 2015 were included in this study, with 293 848 (59.1%) female and 397 295 (79.9%) White participants. As AYAs aged, an increase in the relative incidence of carcinomas and decrease in the relative incidence of leukemias, lymphomas, germ cell and trophoblastic neoplasms, and neoplasms of the central nervous system occurred. Among the female AYAs, 72 564 (24.7%) were diagnosed with breast carcinoma; 48 865 (16.6%), thyroid carcinoma; and 33 828 (11.5%), cervix and uterus carcinoma. Among the male AYAs, 37 597 (18.5%) were diagnosed with testicular cancer; 20 850 (10.2%), melanoma; and 19 532 (9.6%), non-Hodgkin lymphoma. The rate of cancer in AYAs increased by 29.6% from 1973 to 2015, with a mean annual percentage change (APC) per 100 000 persons of 0.537 (95% CI, 0.426-0.648; P < .001). Kidney carcinoma increased at the greatest rate for both male (APC, 3.572; 95% CI, 3.049-4.097; P < .001) and female (APC, 3.632; 95% CI, 3.105-4.162; P < .001) AYAs. In this cross-sectional, US population-based study, cancer in AYAs was shown to have a unique epidemiological pattern and is a growing health concern, with many cancer subtypes having increased in incidence from 1973 to 2015. Continued research on AYA cancers is important to understanding and addressing the distinct health concerns of this population.
Identifiants
pubmed: 33258907
pii: 2773343
doi: 10.1001/jamanetworkopen.2020.27738
pmc: PMC7709088
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2027738Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR002016
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002014
Pays : United States
Références
EJC Suppl. 2014 Jun;12(1):5-17
pubmed: 26217162
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1644-1652
pubmed: 29093004
Cancer. 2008 Jan 15;112(2):416-32
pubmed: 18074355
CA Cancer J Clin. 2019 Nov;69(6):485-496
pubmed: 31594027
Am Surg. 2003 Oct;69(10):866-72
pubmed: 14570365
J Clin Oncol. 2013 Jun 10;31(17):2160-6
pubmed: 23650425
Int J Cancer. 2007 Mar 15;120(6):1336-43
pubmed: 17192897
BMC Cancer. 2015 Nov 11;15:897
pubmed: 26560314
J Natl Cancer Inst. 2019 May 1;111(5):509-518
pubmed: 30321398
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
Am J Epidemiol. 2008 Aug 1;168(3):268-77
pubmed: 18544571
Int J Cancer. 1988 Aug 15;42(2):167-75
pubmed: 3403062
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8
pubmed: 10379968
J Pediatr. 2014 Jun;164(6):1481-5
pubmed: 24630354
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gynecol Oncol. 2015 Sep;138(3):741-9
pubmed: 26080287
Pigment Cell Melanoma Res. 2010 Feb;23(1):57-63
pubmed: 19968819
Br J Cancer. 1996 May;73(9):1134-40
pubmed: 8624277
J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10
pubmed: 12189223
Nat Commun. 2019 Jan 14;10(1):207
pubmed: 30643135
Pediatr Blood Cancer. 2019 Jan;66(1):e27407
pubmed: 30124231
Int J Cancer. 2005 Sep 1;116(3):331-9
pubmed: 15818625
J Urol. 2003 Jul;170(1):5-11
pubmed: 12796635
Cancer Causes Control. 2005 Apr;16(3):309-20
pubmed: 15947883
Med Pediatr Oncol. 2002 Jan;38(1):1-10
pubmed: 11835231
Clin Cancer Res. 2005 Apr 15;11(8):2862-7
pubmed: 15837733
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Cancer. 2016 Sep 1;122(17):2723-30
pubmed: 27286322
Clin Dermatol. 2009 Jan-Feb;27(1):3-9
pubmed: 19095149
Nat Rev Cancer. 2008 Apr;8(4):288-98
pubmed: 18354417
Curr Probl Cancer. 2012 Jul-Aug;36(4):183-90
pubmed: 22481006
J Urol. 2014 Jun;191(6):1665-70
pubmed: 24423441
Lancet. 1983 Nov 26;2(8361):1250
pubmed: 6139593
J Clin Oncol. 2010 Nov 10;28(32):4850-7
pubmed: 20479411
Eur J Cancer. 2003 Sep;39(13):1912-9
pubmed: 12932671